Girardi P1, Rapinesi C, Chiarotti F, Kotzalidis GD, Piacentino D, Serata D, Del Casale A, Scatena P, Mascioli F, Raccah RN, Brugnoli R, Digiacomantonio V,Ferri VR, Ferracuti S, Zangen A, Angeletti G. ...Read More
This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Harel, E. V., Rabany, L., Deutsch, L., Bloch, Y., Zangen, A., & Levkovitz, Y. (2014). The World Journal of Biological Psychiatry, 15(4), 298-306.
This study examined the long-term effect of Brainsway® Deep TMS (Deep Transcranial Magnetic Stimulation) on depressed patients. Patients underwent 4 weeks of intensive treatment and 18 weeks of maintenance treatments. The study demonstrated that brain stimulation using Brainsway’s Deep Transcranial Magnetic Stimulation significantly alleviates depressive symptoms, and that this beneficial effect can be maintained for a long period of time.